Global News

Cromos Pharma launches risk-sharing partnerships program

Friday, December 19, 2014 02:33 PM

Portland, Ore.-based CRO Cromos Pharma, which operates predominantly in Eastern/Central Europe, has implemented a risk-sharing platform partnering with biotech, pharma and device companies with promising drug, biologics or medical device technologies.

More... »


Seven more research organizations earn AAHRPP accreditation

Friday, December 19, 2014 01:02 PM

The Association for the Accreditation of Human Research Protection Programs (AAHRPP) has accredited seven more organizations: four in the U.S. and three in Asia, including the first organization in Thailand.

More... »


Roche acquires Bina Technologies, enters genomic informatics market

Friday, December 19, 2014 01:00 PM

Roche has acquired Bina Technologies, a privately held company based in Redwood City, Calif. Bina provides a big data platform for centralized management and processing of next generation sequencing (NGS) data. Bina's proprietary on-market Genomic Management Solution, Bina-GMS, empowers basic, translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data.

More... »

Merck acquires OncoEthix, a privately-held oncology company

Friday, December 19, 2014 12:06 PM

Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based, privately held biotechnology company specializing in oncology drug development. Merck has gained an investigational, novel oral BET (bromodomain) inhibitor, OTX015, currently in phase Ib studies for the treatment of hematological malignancies and advanced solid tumors.

More... »

RXi Pharmaceuticals, Hapten Pharmaceuticals ink agreement

Friday, December 19, 2014 12:05 PM

RXi Pharmaceuticals, a Marlborough, Mass.,-based biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, has entered into an assignment and exclusive global license agreement with Hapten Pharmaceuticals, an early stage dermatology product development company based in New York, for the therapeutic use of Samcyprone.

More... »

Sorrento, Conkwest collaborate for cancer immunotherapies

Friday, December 19, 2014 12:03 PM

Sorrento Therapeutics, an oncology company based in San Diego, Calif., and Conkwest, a Cardiff-by-the-Sea, Calif.-based, privately-held immuno-oncology company developing proprietary Neukoplast (NK-92), a natural killer cell-line based therapy, have entered into a definitive agreement to jointly develop next generation CAR-TNK immunotherapies for the treatment of cancer.

More... »

Lilly, Adocia ink alliance for ultra-rapid insulin based on BioChaperone

Friday, December 19, 2014 12:02 PM

Eli Lilly and Adocia, a France-based clinical-stage biotechnology company, have announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. BioChaperone Lispro relies on Adocia's proprietary BioChaperone technology and currently is in phase Ib studies.

More... »

Report: Top 30 pharma companies spent $112B on R&D in 2013

Thursday, December 18, 2014 11:19 AM

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on R&D in 2013, an increase of $723 million over the previous year, according to London-based research and consulting firm GlobalData.

More... »

NIH agency gets new name to reflect complementary, integrative health

Thursday, December 18, 2014 11:15 AM

The NIH agency with primary responsibility for research on promising health approaches already in use by the American public has a new name—the National Center for Complementary and Integrative Health (NCCIH).

More... »

Research, generic/biosimilar industries call for integrated strategy for Europe

Thursday, December 18, 2014 11:14 AM

Ahead of the adoption of the European Commission Work Program, the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Generic Medicines Association (EGA) have reiterated their joint Europe 2020 strategy submission for an industrial policy for the globalization era and the value it places in the pharmaceutical sector. The joint submission highlights key proposals on how to successfully integrate the pharmaceutical sector for an industrial policy that will boost European health and wealth alike.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs